Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

Author(s):

Robert M. Rifkin, MD, FACP, discusses how real-world studies on teclistamab and talquetamab presented at ASH 2024 reinforce their efficacy and impact on patient outcomes in relapsed/refractory multiple myeloma, while panelists discuss how clinicians should prioritize factors such as patient characteristics and treatment history when selecting the most appropriate bispecific therapy for these patients.

Now Viewing

EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

Video content above is prompted by the following:

Real-world studies on teclistamab and talquetamab (tal-quit-amab) presented at ASH 2024 highlighted their efficacy and patient outcomes outside clinical trials. How do these findings align with clinical trial data, and what differences (if any) stood out to you in the real-world setting?
Based on the real-world evidence shared for teclistamab and talquetamab, what factors should clinicians prioritize when selecting the appropriate bispecific therapy for patients with relapsed/refractory multiple myeloma?